A B S T R A C T Immunologic function was evaluated in 12 patients with Hodgkin's disease and 5 patients with lymphocytic lymphoma who had been successfully treated with either chemotherapy, radiation therapy, or both of these modalities 3-42 mo previously. Only two of the patients were found to have total anergy to a battery of six recall skin test antigens and all were responsive to skin testing with phytohemagglutinin. However, 10 of 16 patients were unable to develop delayed cutaneous hypersensitivity to either of the neoantigens dinitrochlorobenzene or keyhole limpet hemocyanin. Four other patients developed reactivity to only one of these neoantigens for a total of 14 of 16 (88%) of the patients demonstrating some impairment in neoantigen response.
A B S T R A C T Immunologic function was evaluated in 12 patients with Hodgkin's disease and 5 patients with lymphocytic lymphoma who had been successfully treated with either chemotherapy, radiation therapy, or both of these modalities 3-42 mo previously. Only two of the patients were found to have total anergy to a battery of six recall skin test antigens and all were responsive to skin testing with phytohemagglutinin. However, 10 of 16 patients were unable to develop delayed cutaneous hypersensitivity to either of the neoantigens dinitrochlorobenzene or keyhole limpet hemocyanin. Four other patients developed reactivity to only one of these neoantigens for a total of 14 of 16 (88%) of the patients demonstrating some impairment in neoantigen response.
Total lymphocyte, T-lymphocyte, B-lymphocyte, and null cell numbers, as well as serum immunoglobulins were quantitatively normal. Monocyte numbers, chemotaxis, and Fc receptor activity were normal. Monocyte staphylocidal activity at 60 min was modestly depressed and candidacidal activity was depressed in those receiving both chemotherapy and radiation therapy.
Spontaneous (unstimulated) lymphocyte [8H]thymidine incorporation was low in the patients as a group and lymphoblastic transformation to specific antigens was impaired in 11 of 17 patients who had positive skin test reactions to the same antigen. Highly significant suppression of lymphoblastic transformation was noted after stimulation by the mitogens phytohemagglutinin, pokeweed, and concanavalin-A. The greatest impairment of mitogen response was seen in those patients receiving both chemotherapy and radiation therapy.
INTRODUCTION
Modern therapy for patients with Hodgkin's and nonHodgkin's lymphoma has advanced to the point that prolonged unmaintained remissions and possibly even cures are becoming the rule rather than the exception (1) . Although immunologic defects have been well characterized in untreated patients with lymphoma (2-12), relatively little is known about the immune status of patients successfully treated with intensive combination chemotherapy and/or radiation therapy who are in unmaintained remission (6) .
Patients with untreated Hodgkin's disease have been the most extensively studied and commonly appear to have evidence of impaired cellular immunity. These abnormalities include lymphopenia and impaired response to recall skin tests, neoantigens, and homografts as well as defective in vitro lymphocyte reactivity (2) (3) (4) (5) (6) (7) (8) . Patients with non-Hodgkin's lymphoma have been studied less extensively, but the described defects primarily involve humoral immune function (5 (13) . Other authors have related an increased incidence of acute leukemia to successful radiation therapy for Hodgkin's disease (14) .
The purpose of this study was to evaluate the immune function of successfully treated lymphoma patients and to correlate the findings with diagnosis, type of therapy, and duration of remission. Seventeen patients with lymphoma who had completed successful chemotherapy, radiation therapy, or a combination of the two were utilized in this study. These evaluations were performed at times sufficiently remote from their treatment to avoid monitoring the acute effects of radiation or chemotherapy. 10 bl/106 cells, and concanavalin A (Con-A, Pharmacia Laboratories, Piscataway, N. J.) 25 ,ug/106 cells. Antigen-stimulated LBT was performed with tuberculin, trichophyton, SK/SD, and candida utilizing a dose-response curve for each antigen. The maximum response was used in evaluation of LBT.
METHODS
Lynmphocyte quiantitation. The E-rosette assay for identification of T-lymphocytes using sheep erythrocytes was performed according to the method of Jondal et al. (21) . The erythrocyte-antibody complement (EAC) assay for complement (C3) receptors of B-lymphocytes was performed according to the method of Bianco et al. (22) . Im M, and A were determined according to the method of Killingsworth and Savory (27) .
Statistical analyses. Data were analyzed with the t test for independent samples (28) . RESULTS Personal data for the treated lymphoma patients are listed in Table I . The mean age of the patients was 39 yr and there was a relatively equal distribution of men and women in each diagnostic and treatment category.
The duration of unmaintained remission varied from 3 to 42 mo with a median of 16 mo. Thus, one-half of the subjects had been off all treatment for almost 11 yr.
Skin tests. Only two of the patients studied were totally anergic to the battery of recall skin test antigens (Table II) and both of them had HD (L. L. and R. R.). Of the recall antigens tested, mumps, SK/SD, and histoplasmin were the most consistently positive at 82, 47 and 41%, respectively. All the patients had a normal response to skin testing with PHA supporting the evidence for an intact ability to mount a normal mononuclear cell infiltrate.
Neoantigen sensitization. One of the most significant abnormalities noted in these patients was the inability to be sensitized by the neoantigens DNCB and KLH (Table II) . 10 - is shown in Fig. 1 . Compared to lymphocytes of 10 normal subjects, the patients' lymphocytes had a significantly lower ['H]TdR uptake after a 3-day culture period. Although nine of the patients had values within the normal range, differences between the two groups were highly significant at P <0. (Fig. 2B ), those patients who had received both chemotherapy and radiation therapy had the poorest response to all three mitogens. Of course, it should be noted that only three of the patients received chemotherapy alone.
When LBT was evaluated in terms of individual increments above unstimulated ['H]TdR uptake, the same patterns of response were noted in each category with an apparent increase in statistical significance being noted. Analysis of the data using stimulation ratios revealed variable results due to the variability in baseline values, but significant impairment of LBT was identified in the Hodgkin's disease patients with Con-A (P < 0.001) and PWM (P < 0.01), the radiation therapy (RT) patients with PWM (P < 0.05) and chemotherapy and radiation therapy (CT-RT) patients with Con-A (P < 0.001) and PWM (P < 0.001).
LBT to specific antigens. (Table IV) . Four patients had lymphocytosis and two patients were lymphopenic. Generally, the patients with lymphocytosis had increased numbers of both B and T cells except for patient R. R. whose lymphocytosis appeared to be due largely to cells lacking membrane markers (null cells). Both patients with lymphopenia had reduced numbers of T cells. One patient (C. S.) with a borderline low lymphocyte count and lower limits of normal T cells had almost complete absence of B cells as measured by both Monocyte function studies. The patients as a group had normal absolute numbers of blood monocytes (441+ 144/mm3). Monocyte chemotaxis to two stimuli and membrane Fc receptor activity were normal (Table V) . Although a modest decrease in monocyte staphylocidal activity was noted at 60 min (P < 0.02), all but two of the patients fell within the normal range. No significant differences from normal were noted when the data were evaluated on the basis of diagnosis or therapy. Candidacidal activity was not significantly impaired in the patient group as a whole. However, four of the patients (3 HD, 1 LL) were clearly below the normal range. When evaluated on the basis of diagnosis and 1456
King, Yanes, Hurtubise, Balcerzak, and LoBuglio treatment, significant differences in candidacidal activity were found between normals and those patients who had received both CT and RT (6.2±2.8 X 10' organisms killed, P < 0.05).
Correlations. Attempts to correlate the observed alterations in lymphocyte function and neoantigen response with other characteristics of the patients were for the most part disappointing. Although most of the patients had LBT to all mitogens below the normal range (PHA 10/17, Con-A 14/17, and PWM 12/17), no correlation could be made between these functional impairments and total lymphocyte quantitation or number of B cells, T cells, or null cells. Also, no significant correlation was found between impaired LBT or neoantigen response and initial stage of disease or duration of unmaintained remission.
The most significant correlations were found in the relationship of lymphocyte function to type of therapy with the majority of the patients with impaired LBT having received CT/RT. Although statistically significant differences between the RT and CT/RT could only be defined with PHA stimulation (P < 0.02), the distribution (Fig. 2B) would suggest that except for a few individuals, CT/RT had a greater suppressive effect on the lymphocyte response to all the mitogens than did RT. CT alone appears to have the least long term effect of the three therapeutic modalities, but only three of our patients received CT alone making this point difficult to support. HD also would appear to be associated with a greater suppression of LBT than LL as far as distribution of individual values is concerned, but this difference is not statistically significant.
DISCUSSION
This study clearly demonstrates impaired cellular immunity in patients with lymphoma who are in prolonged, unmaintained remission after successful treatment with CT and/or RT. This impairment is documented in several ways. First, and most striking, is the observed impairment in developing delayed hypersensitivity to the neoantigens DNCB and KLH. Immunization with these antigens is almost always successful in normal subjects (2) and yet 11 of 16 (69%) of our patients failed to develop delayed hypersensitivity to the neoantigen DNCB and 13 of 16 (81%) failed to respond to KLH. The incidence of failure to respond to DNCB sensitization has been reported to be 30-100% (2, 10) in untreated HD patients but the response to KLH in lymphoma patients is unclear. This impairment in developing delayed hypersensitivity to neoantigens occurred despite a normal response to skin testing with the mitogen PHA and relatively normal skin testing with a battery of recall antigens. All of the patients developed erythema and induration 24 h after primary injection of PHA and only two of the patients failed to respond to any of the recall antigens. Neither of the anergic patients had any suppression of total lymphocyte counts or circulating T-cells and monocyte chemotaxis was normal. In view of these observations we interpret the failure to respond to DNCB and KLH as a defect in initiating a primary immune response since (a) lymphocyte and monocyte numbers were intact, (b) immunologic memory was relatively intact (recall skin testing), and (c) the effector arm of the delayed hypersensitivity response was normal (PHA skin testing and monocyte chemotaxis).
Another grossly abnormal function was the response of the patients' lymphocytes to in vitro stimulation with mitogens. Impaired responses to PHA occurred at least as frequently as reported by others in untreated patients (3, 4, 6, 7, 12, 28) but no correlation could be made with T-cell or total lymphocyte numbers, a point in contrast to previous reports of untreated patients (29, 30) . Impaired response to Con-A and PWM was even more striking. This pattern is quite different from that reported for untreated HD patients where impairments in PHA responsiveness appear to be more severe than PWM (3). The impaired response to PWM was not associated with any decrease in blood lymphocytes or B-cell levels, suggesting a qualitative disturbance of B-cell response to mitogen stimulation. Other studies have reported chronic depression of B-cell numbers and impaired PWM response in radiated cancer patients (31) or increased B-cell numbers (32, 33) and normal PWM response (33) after RT of lymphoma.
Finally, a more difficult area to interpret is the noted disparity between LBT to antigens and skin test response to the same antigens. Churchill et al. have reported almost unanimous correlation of skin test reactivity and LBT to antigens in normal subjects and a frequent occurrence of positive LBT to an antigen with negative skin test to the same antigen in patients with untreated HD. They did not observe the converse, i.e., positive skin test and negative LBT and concluded that there was a nonlymphocyte defect in the immune response of their lymphoma patients (34 (36) and that this is not a valid means of assessing cellular function in individual patients. However, the incidence of such disparities in our treated lymphoma patients seems inordinately high.
Although the question of impaired monocyte function is raised by the foregoing studies of skin test reactivity and LBT to antigens, we were unable to demonstrate any significant impairment of monocyte chemotaxis by our in vitro assays utilizing two stimuli. This suggests that movement of the monocytes into sites of skin tests should have been intact and is further supported by the normal response to PHA skin testing which is thought to depend on mononuclear cell migration into the site of nonspecifically stimulated lymphocytes. The normal to slightly decreased microbicidal activity is probably more significant than is readily apparent in that untreated lymphoma patients have enhanced monocyte microbicidal activity against staphylococcus organisms (26) . Apparently, eradication of the disease and/or therapy results in a decrease in microbicidal activity as compared to untreated lymphoma patients. Although staphylocidal activity was significantly lower than normal at 60 min, this modest change is probably not biologically significant since only two of the patients fell outside the normal range. Candidacidal activity was only impaired in those patients who had received both CT and RT, a point of possible significance since it would seem that this group had the greatest impairment of lymphocyte function.
These observations on the immune status of successfully treated lymphoma patients can be interpreted in several ways. First, the skin test anergy, impaired response to neoantigens, and in vitro lymphocyte abnormalities are similar to those of untreated patients and may indicate that the immune deficits associated with acute disease are not reversible with successful therapy. Second, therapy may have successfully eradicated disease and replaced the immune deficits due to disease with deficits due to irradiation and/or CT (37, 38) . Third, these deficits may represent a combination of some residual disease related abnormalities and the addition of therapy-induced defects. We would suggest that therapy is at least contributing to the in vitro abnormalities noted in lymphocyte function. Studies of a large number of successfully treated lymphoma patients are underway in the Southwest Oncology Group (Kansas City, Kansas) to allow correlation of immune status with stage of disease, histologic subtypes, type of therapy, incidence of infection or second malignancy and ultimate prognosis.
The observed defects in these patients may well contribute to an increased incidence of infectious complications but the role of these defects in the development of second malignancies is unclear. Canellos et al. (13) observed the greatest incidence of second primary malignancies in those HD patients who had received both CT and RT. It is tempting, therefore, to speculate that the immune functional abnormalities noted in our study are responsible for the development of these malignancies since there is at least a suggested greater impairment of lymphocyte function and monocyte function in this treatment group. However, one might also ask why the incidence of second malignancies does not more closely parallel the incidence of immunologic abnormalities if immunocompetence is so important in the resistence of these second cancers. Indeed, the entire concept of immune surveillance being important in the resistence of cancer is now being debated (39) .
Another consideration in reference to the increased incidence of cancer in treated lymphoma patients is whether or not the therapy itself is oncogenic. There is good evidence that both ionizing irradiation (40) and CT with alkylating agents (41) are associated with an increased incidence of primary malignancies in man, and, of course, the treatment of lymphoma involves these modalities. None of these questions can be answered by our study but expansion of these studies to larger numbers of patients with a more prolonged period of observation may clarify these important relationships. It may well be that as radiation and CT of other tumors becomes more successful, the problem of second malignancies will be seen in increasing numbers of these patients as well.
